与控股股东“房产混用”，通化东宝董事长收警示函

Group 1 - The core point of the article is that Tonghua Dongbao received a warning from the Jilin Securities Regulatory Bureau due to issues regarding the independence of the company and its major shareholder, Dongbao Industrial Group [1][3] - The company has been found to have mutual use of certain properties with its controlling shareholder without signed lease agreements or rent payments, indicating a lack of independence [3] - The chairman, Li Jiahong, is primarily responsible for these violations, and the regulatory body has decided to impose corrective measures and issue a warning letter [3] Group 2 - On January 29, Dongbao Industrial Group pledged 21 million shares of Tonghua Dongbao to China Construction Bank for debt repayment, representing 1.07% of the company's total share capital [3] - As of the announcement date, Dongbao Industrial Group holds a total of 620 million shares, with 586 million shares pledged, accounting for 29.94% of the total share capital and 94.66% of the shareholder's holdings [3] - Just days before the warning letter, Tonghua Dongbao announced a positive earnings forecast for 2025, expecting a net profit of approximately 1.242 billion yuan, marking a significant turnaround from the previous year [3][4] Group 3 - The company's turnaround in performance is attributed to two main factors: the successful bidding for insulin products in the domestic market and significant growth in other products like liraglutide injection and empagliflozin tablets [4] - Notably, a substantial portion of the net profit increase is due to a one-time gain from the sale of shares in Xiamen Te Bao Biological Engineering Co., which contributed over 800 million yuan, accounting for about 64% of the total net profit [4][5] - This indicates that the impressive performance in 2025 is largely driven by a non-recurring asset sale rather than core business operations [5]